Real-Time Oncology Review (RTOR) is a voluntary FDA Oncology Center of Excellence (OCE) program that lets sponsors submit key efficacy and safety datasets to FDA on a rolling basis, ahead of a complete formal application, so review staff can begin analysis before the (supplemental) new drug application or biologics license application is formally filed. It is a change to how and when data reaches reviewers, not a new approval standard or a change to what evidence is required — that distinction matters for research administrators coordinating a submission timeline, because RTOR reshapes internal deadlines for data lock, statistical analysis, and manuscript-adjacent summary documents well before the nominal “submission date” that appears in a regulatory tracker.
This guide is specific to RTOR itself: what it is, who is eligible, how the rolling-submission process works, and how it relates to (and differs from) the adjacent FDA oncology programs it’s most often confused with, including Project Orbis, the Assessment Aid, and the classic expedited-program quartet of Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review. For a related but distinct FDA OCE initiative — one governing dose selection rather than review timing — see CASRAI’s guide to FDA’s Project Optimus.
What Is Real-Time Oncology Review (RTOR)?
RTOR is a pilot review process, run by FDA’s Oncology Center of Excellence, that allows interactive, ongoing engagement between a sponsor and FDA review staff so that analysis of a product’s data can begin before a complete supplemental or original application is submitted. In a standard submission, FDA review begins only once the full application — including complete datasets, statistical analyses, and administrative components — has been filed. Under RTOR, a sponsor instead submits topline efficacy and safety datasets earlier, often once the pivotal trial’s key analyses are available, and FDA reviewers begin working through that data while the sponsor finishes assembling the remaining components of the full application.
The intended effect is to surface data-quality questions and substantive review issues earlier, when there is still time for the sponsor to address them before the formal application clock starts, which FDA describes as enabling a more efficient, less bottlenecked review overall. Participation is voluntary on the sponsor’s part, and FDA can also decide participation is no longer appropriate at any point and direct the applicant back to routine submission procedures.
History: From a 2018 Pilot to a Finalized Guidance
FDA launched RTOR in 2018, initially limited to supplemental applications for products already approved for a different indication. Later that same year, FDA expanded the program’s scope to include original applications for new molecular entities (NMEs) meeting the program’s eligibility criteria, not just supplements to existing approvals. FDA issued draft guidance formalizing the program’s eligibility and submission expectations in July 2022, and finalized that guidance in November 2023 (published in the Federal Register on November 8, 2023), which is the current authoritative description of how the program operates procedurally.
Eligibility: What Makes an Application a Fit for RTOR
FDA has described RTOR candidates in terms of straightforward study designs and endpoints that are relatively easy to interpret — the kind of dataset a reviewer can assess quickly without extensive independent re-analysis. In practice, this has meant RTOR-eligible applications are frequently supported by randomized controlled trials with simple designs (for example, a two-arm comparison) and by a product that is expected to represent a substantial improvement over available therapy for the indication in question. Eligibility is not self-declared: sponsors typically raise RTOR participation with FDA during ongoing interactions with the review division (for example, at a mid- or end-of-Phase-2 meeting, or another point where the planned pivotal trial and its data package are already under discussion), and FDA determines whether the program is a fit for that specific application.
RTOR eligibility is a procedural determination about how an application will be reviewed — it is not itself a designation with a formal legal status, and it is not the same evidentiary bar as, for example, orphan drug designation or accelerated approval. Because the two are frequently discussed together, it’s worth being precise: a product can carry Breakthrough Therapy Designation or qualify for Accelerated Approval and separately also be accepted into RTOR, but none of these is a prerequisite for, or automatic consequence of, another.
How the Rolling Submission Process Works
Once FDA and a sponsor agree an application is a fit for RTOR, the practical process differs from a standard filing in a few concrete ways:
- Data arrives before the formal application. The sponsor submits datasets — typically the topline efficacy and safety results from the supporting trial(s) — to FDA ahead of submitting the complete (supplemental) NDA or BLA, rather than assembling everything and filing once.
- FDA reviews on a rolling basis. Review staff begin working through the submitted datasets as they arrive, rather than waiting for the full package, which is intended to surface data-quality or interpretive questions while there is still time to resolve them before the formal filing.
- The Assessment Aid often accompanies the process. If a sponsor is participating in RTOR, it may submit the Assessment Aid — a structured summary document FDA reviewers use as a working reference — before or at the time of the (supplemental) NDA/BLA submission, rather than as part of a lengthy separate summary document assembled after the fact.
- The formal application still gets filed. RTOR does not replace the requirement to file a complete application; it changes when FDA’s substantive review of the underlying data effectively begins relative to that filing date.
For sponsors and the research administration teams supporting them, the practical consequence is that internal deadlines shift earlier. Data lock, database cleaning, and the statistical analysis plan’s execution need to be substantially complete well before what would, under a standard timeline, be considered an early planning stage — because that data is what gets submitted to FDA first, before the rest of the application is assembled.
RTOR vs. Standard Review: What Actually Changes
| Dimension | Standard Review | RTOR |
|---|---|---|
| When FDA review begins | After the complete application is filed | On a rolling basis, as topline datasets arrive, before the complete application is filed |
| Evidentiary standard | Full efficacy/safety data package required | Same underlying evidentiary standard — RTOR changes submission timing and process, not what evidence is required |
| Applicability | Any application | Oncology applications with straightforward designs/endpoints that FDA agrees are a fit |
| Participation | Not applicable | Voluntary; FDA can also end a sponsor’s participation and revert to standard procedures |
RTOR and Project Orbis: Related but Distinct Programs
RTOR is sometimes discussed alongside Project Orbis, another FDA Oncology Center of Excellence initiative, and the two are often used together, but they address different problems. Project Orbis, launched in May 2019, is a framework for concurrent submission and review of oncology marketing applications by multiple international regulatory authorities at once — participating authorities have included Australia’s TGA, Health Canada, Switzerland’s Swissmedic, the UK’s MHRA, Singapore’s HSA, Brazil’s ANVISA, and Israel’s Ministry of Health, alongside FDA. RTOR, by contrast, is specifically about the timing and structure of FDA’s own domestic review process. A sponsor can participate in both programs for the same application — using RTOR’s rolling-submission process for the FDA review while also filing concurrently with Project Orbis partner authorities — but each program has its own eligibility conversation with FDA and neither participation is contingent on the other.
RTOR vs. Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review
RTOR is frequently conflated with FDA’s four classic expedited-program designations, but it operates on a different axis. Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review are formal designations that a sponsor requests and FDA grants (or denies) based on criteria such as unmet medical need, preliminary evidence of substantial improvement, or reliance on a surrogate endpoint — and each carries specific procedural or evidentiary consequences (for example, Accelerated Approval permits approval based on a surrogate endpoint subject to post-marketing confirmatory trial requirements). RTOR is not a designation in this sense: it doesn’t change what evidence is required or create a surrogate-endpoint pathway. It is a process for restructuring when FDA reviewers see the data that supports whatever pathway and designations the application already carries. CASRAI covers the four designation-based programs in detail in FDA Expedited Programs: Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review Compared — that guide is the reference for the designations themselves; this page is the reference for RTOR’s rolling-review mechanics.
Limitations and What RTOR Does Not Do
- It is not a guarantee of approval or of a faster ultimate decision in every case. RTOR restructures when review begins; it does not change FDA’s substantive standard for approval, and a sponsor can still receive a Complete Response Letter after an RTOR-supported review.
- It is not available on request for any oncology application. FDA determines fit based on straightforward study design, an easily interpreted endpoint, and an expectation of substantial improvement over available therapy — not every oncology submission qualifies.
- Participation can be rescinded. If FDA determines at any point that RTOR is no longer appropriate for a given application, the sponsor is directed back to routine submission procedures.
- It does not reduce the underlying evidentiary bar. The clinical trial(s) supporting an RTOR-reviewed application must still meet the same substantive standards — including, where applicable, the trial design and endpoint conventions covered in CASRAI’s guide to what makes oncology clinical trials different — as any other application.
What RTOR Means for Research Administration Teams
For research administrators and clinical operations staff supporting an oncology sponsor, RTOR’s main operational effect is compressing the internal timeline that precedes the nominal submission date. Because topline datasets go to FDA before the full application is assembled, database lock, query resolution, and the statistical analysis plan’s execution need to land earlier relative to when the organization might otherwise have treated “submission” as the driving deadline. Coordinating that shift — and making sure clinical data management, biostatistics, and regulatory affairs are aligned on an accelerated internal calendar — is itself a project-management function that sits alongside, not instead of, the standard regulatory submission planning covered in CASRAI’s broader clinical research administration coverage.
Frequently Asked Questions
Does RTOR apply to biologics (BLAs), or only new drug applications (NDAs)?
RTOR applies to both. FDA’s guidance covers real-time review for oncology (supplemental and original) new drug applications and biologics license applications alike; the program is defined by the oncology indication and eligibility criteria, not by whether the product is regulated as a drug or a biologic.
Is RTOR mandatory for oncology submissions?
No. Participation is voluntary for the sponsor, and FDA separately decides whether a given application is a fit for the program. Sponsors that don’t participate, or whose applications aren’t accepted into RTOR, use the standard submission and review process.
Does RTOR guarantee a faster overall approval timeline?
RTOR restructures when FDA review begins relative to the formal filing, which is intended to reduce review bottlenecks, but it is not a guarantee of a faster ultimate decision or of approval itself. A product reviewed under RTOR can still receive a Complete Response Letter or otherwise not be approved.
How is RTOR different from a Priority Review designation?
Priority Review is a formal designation that shortens FDA’s target review clock (historically to eight months from the standard ten, from the date of filing) once a complete application is filed. RTOR changes when substantive review of the underlying data begins relative to that filing, not the length of the review clock itself. The two can apply to the same application simultaneously.
Where is the current, authoritative description of RTOR’s process?
FDA’s finalized guidance, “Real-Time Oncology Review (RTOR) — Guidance for Industry,” published in November 2023, is the current authoritative procedural reference, alongside FDA’s Oncology Center of Excellence program pages.
